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Abstract
Background—Observational data have demonstrated an association between higher 
ultrafiltration (UF) rates and greater mortality among hemodialysis (HD) patients. Prior studies 
were small and did not consider potential differences in the association across body sizes and other 
related subgroups. No study has investigated UF rates normalized to anthropometric measures 
beyond body weight. Also, potential methodological shortcomings in prior studies have led to 
questions about the veracity of the UF rate–mortality association.
Study Design—Retrospective cohort.
Setting & Participants—118,394 HD patients dialyzing in a large dialysis organization, 2008–
2012.
Predictors—Mean 30-day UF rates were dichotomized at 13 and 10 mL/h/kg, separately, and 
categorized using various cut-points. UF rates normalized to body weight, body mass index and 
body surface area were investigated.
Outcomes—All-cause mortality.
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Measurements—Multivariable survival models were used to estimate the association between 
UF rate and all-cause mortality.
Results—At baseline, 21,735 (18.4%) individuals had UF rates >13 mL/h/kg and 48,529 
(41.0%) had UF rates > 10 mL/h/kg. Median follow-up time was 2.3 years, and the mortality rate 
was 15.3 deaths per 100 patient-years. Compared to UF rates ≤13, UF rates >13 mL/h/kg were 
associated with greater mortality (adjusted HR, 1.31; 95% CI, 1.28–1.34). Compared to UF rates 
≤10, UF rates >10 mL/h/kg were associated with greater mortality (adjusted HR, 1.22; 95% CI, 
1.20–1.24). Findings were consistent across subgroups of sex, race, dialysis vintage, session 
duration, and body size. Higher UF rates were associated with greater mortality when normalized 
to body weight, body mass index, and body surface area.
Limitations—Residual confounding cannot be excluded given the observational study design.
Conclusions—Regardless of the threshold implemented, higher UF rate was associated with 
greater mortality in the overall study population and across key subgroups. Randomized controlled 
trials are needed to investigate whether UF rate reduction improves clinical outcomes.
Index words—hemodialysis, mortality, ultrafiltration rate (UFR), body size, body weight, body 
mass index (BMI), body surface area (BSA), anthropometric measures, metabolic mass, rapid 
fluid removal, end-stage renal disease (ESRD)
Hemodialysis (HD) patients have high rates of morbidity and mortality.1 Fluid removal 
practices likely contribute to these poor outcomes. Existing data support an association 
between more rapid fluid removal during dialysis and greater mortality.2–4 End-organ 
ischemia of the heart, brain and gut from overt and subclinical hemodynamic instability 
plausibly underlie this association.5–8 Ultrafiltration (UF) rate is quantifiable and represents 
a modifiable fluid-related aspect of the HD prescription that is potentially within dialysis 
facility control. Currently, the Centers for Medicare & Medicaid Services (CMS) is 
considering an UF rate threshold of 13 mL/h/kg as a quality measure to assess dialysis 
facility fluid management, and such a threshold has been incorporated into the CMS 2016 
End Stage Renal Disease Core Survey.9,10
Three observational investigations have demonstrated harm from greater UF rates.2–4 
However, the studies are modestly sized, precluding robust analyses among key subgroups 
with plausibly different UF rate–outcome associations. The UF rate threshold delineating 
heightened risk may vary by patient type, which, if true, would make a single UF rate 
benchmark inappropriate as a quality measure. Patient characteristics such as body size and 
composition influence total body water distribution and plasma refill, making body size and 
its correlating factors of race and sex plausible modifiers of the UF rate–outcome 
association. Additionally, UF rates are typically normalized to body weight. However, UF 
rate normalization to other anthropometric measures that may capture metabolic mass better 
has not been evaluated. Finally, potential shortcomings in prior analyses may have biased 
risk estimates. Investigators included interdialytic weight gain (IDWG), session duration, 
and weight, all UF rate calculation components, in multivariable models. Such inclusion 
may obscure the true association between UF rates and outcomes.11 The aforementioned 
uncertainties, along with the observational nature of the data, have led to reluctance by 
guideline bodies such as NKF-KDOQI (National Kidney Foundation–Kidney Disease 
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Outcomes Quality Initiative) to issue firm UF rate guidelines and questions about the 
appropriateness of a single, weight-based UF rate threshold for all patients.12,13
We undertook this study to further investigate the association of UF rate and mortality in a 
large, prevalent HD patient cohort. We examined the UF rate–mortality association across 
body size, sex, race, dialysis vintage, and HD session duration subgroups. We also 
investigated the robustness of the UF rate–mortality association across UF rate calculations 
normalized to different anthropometric measures.
METHODS
Study Design
Data were obtained from a cohort of 337,863 patients receiving HD at a single large dialysis 
organization (LDO) from June 2008 through December 2012. Figure 1 displays study 
design. Patients were included if they were age 18 years or older, received in-center HD, and 
had been on dialysis for ≥90 days at study entry. Exclusion criteria included the occurrence 
of death or censoring event during the exposure period, <7 in-center HD treatments during 
the exposure period, and missing UF rate data. We identified all in-center HD patients who 
met study eligibility criteria as of June 1, 2008 (study start date). For patients entering the 
LDO database later in calendar time, eligibility criteria was assessed on the first outpatient 
HD treatment date in the data. This date was the study entry date for patients entering the 
cohort after June 1, 2008.
Demographic characteristics (age, sex, race, height, and dialysis vintage) and comorbid 
conditions (diabetes, heart failure, coronary disease) were considered as of cohort entry. 
Laboratory and HD treatment data were captured in a 30-day baseline period. Laboratory 
covariates (urea reduction ratio [URR], albumin, sodium, creatinine, hemoglobin, and 
phosphate) were considered as the last non-missing values in the baseline period. Pre-
dialysis systolic blood pressure (SBP) was considered as the mean of values in the baseline 
period. Ultrafiltration rates were assessed in a 30-day exposure period following the baseline 
period. Patients surviving the baseline and exposure periods (to study day 60) were followed 
forward in historical time to death, censoring event, or study end (December 31, 2013).
This study was approved by the University of North Carolina at Chapel Hill Institutional 
Review Board (IRB number 15–2100). Given the large cohort size, data anonymity, and 
nonintrusive research, informed consent requirements were exempted.
Data Collection
All data were obtained from the LDO’s medical record. Demographics were recorded upon 
admission to an organization facility. Comorbid conditions were determined by a 
nephrologist at the time of patient entry to the LDO and updated based upon clinical course. 
Laboratory results were measured biweekly or monthly. Dialysis treatment data including 
session duration and pre- and post-dialysis weights were recorded on a treatment-to-
treatment basis. Interdialytic weight gain was defined as pre-dialysis weight (kg) minus 
post-dialysis weight (kg) from the previous treatment. Based on review of relevant medical 
records and per standardized LDO protocol, death dates were recorded by facility personnel.
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Designation of Exposures and Outcome
In primary analyses, prescribed UF rate normalized to body weight (mL/h/kg) was 
calculated as follows: IDWG (kg)/prescribed session duration (h)/post-HD weight (kg) for 
each exposure period HD treatment. Prescribed UF rate was assumed constant during each 
treatment and was considered as a mean of UF rate values over the 30-day exposure period. 
A 30-day exposure period was selected a priori to limit survivorship bias and to mirror prior 
analyses.3,4 Sixty and 90-day periods were considered in sensitivity analyses, and results 
were analogous (Table S1, available as online supplementary material). Additional 
sensitivity analyses considered time-updated UF rate and mortality.
In primary analyses, prescribed UF rate was treated as binary (≤10 versus >10 mL/h/kg and 
≤13 versus >13 mL/h/kg, separately) to mirror the dichotomized approach of quality 
measures.14 Secondary analyses considered categorized UF rates (<10, 10–13, and >13 
mL/h/kg) consistent with prior studies2,4 and more granular UF rate categories (<6, 6–<8, 8–
<10, 10–<12, 12–<14, and ≥14 mL/h/kg). To evaluate for a dose-response relationship, we 
constructed a frequency-based UF rate exposure definition. We considered the proportion of 
HD treatments in the exposure period with UF rates >13 mL/h/kg: <25%, 25–50%, and 
>50% of treatments. We selected a threshold of 13 mL/h/kg to mirror the CMS surveyor tool 
cut-point.10 We conducted additional analyses considering delivered UF rates. Delivered UF 
rate indexed to body weight (mL/h/kg) was calculated as: UF volume (mL)/delivered session 
duration (h)/post-HD weight (kg).
Secondary analyses were performed considering UF rate normalized to body mass index 
(BMI, kg/m2) and body surface area (BSA, m2), separately. To mirror primary analyses, 
BMI and BSA were calculated based on post-HD weight. The BSA was calculated 
according to Du Bois.15 In these analyses, UF rate to BMI (mL/h/kg/m2) and UF rate to 
BSA (mL/h/m2) were dichotomized at the 80th percentiles. The 80th percentile threshold was 
selected to mirror the primary analysis, as 13 mL/h/kg represented the 80th percentile of UF 
rate normalized to body weight.
The outcome of interest was all-cause mortality. Patients were considered at-risk for the 
study outcome following the exposure period and remained at-risk until death or censoring 
for loss to follow-up or study end (December 31, 2013). Dialysis modality change and 
kidney transplantation were treated as competing risks.16
Statistical Analyses
Analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC). Baseline 
patient characteristics were described across UF rate groups as counts and proportions for 
categorical variables and as means ± standard deviations for continuous variables.
Time-to-event analyses were conducted using unadjusted and adjusted Fine and Gray 
proportional subdistribution hazards regression models to estimate hazard ratios (HRs). The 
proportionality assumption was confirmed via Schoenfeld residual testing. Missing values of 
laboratory variables were imputed using the Markov chain Monte Carlo method with 10 
imputations (albumin, n=2,184; creatinine, n=7,473; phosphorus, n=1,430; hemoglobin, 
n=627; and URR, n=1,642).17 Implausible values of pre- and post-HD weight, session 
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duration, and post-HD weight were considered missing. Collinearity of exposure and model 
covariates was evaluated by the variance inflation factor. Interdialytic weight gain, session 
duration, and post-HD weight demonstrated moderate collinearity with UF rate and were 
excluded from the model (variance inflation factor ≥1.3 versus =1.0 for all other model 
variables).
Effect modification of the UF rate–mortality association on the basis of sex, race (black 
versus non-black), ethnicity (Hispanic versus non-Hispanic), body weight (<20th versus 
>80th percentile of post-HD weight), dialysis vintage (<4 versus ≥4 years), and session 
duration (<4 versus ≥4 h) was explored through restriction subgroup analyses. Significance 
of interaction was assessed by the Wald test of nested models that did and did not include 
two-way cross product terms. Restricted analyses, using the same analytic methods as 
primary analyses, were performed in subgroups of interest (session duration ≥4 h and 
dialysis vintage ≥4 years). In secondary analyses the Vuong test was used to compare the 
relative mortality predictive value of UF rates normalized to body weight, mL/h/kg, (versus 
BMI, mL/h/kg/m2, and BSA, mL/h/m2, separately) based on the cumulative incidence 
function of fully adjusted models.18
In sensitivity analyses, we assessed the association between time-updated UF rate (mL/h/kg) 
and mortality using marginal structural proportional hazards models. Marginal structural 
models estimate the effect of a time-varying exposure on an outcome by controlling for the 
effects of time-dependent confounders.19,20 Table a and figure a of Item S1 provide detailed 
methods.
RESULTS
Cohort Characteristics
Figure 2 displays a flowchart of patient selection. Table 1 displays cohort characteristics 
across prescribed UF rate groups. Compared with patients with UF rates ≤13 mL/h/kg, 
patients with UF rates >13 mL/h/kg had smaller body sizes, were younger, and were more 
likely to be female, non-black, Hispanic, and have comorbid heart failure, longer dialysis 
vintage, shorter session durations, and larger IDWGs. Table S2 displays comparisons of 
included and excluded patients.
Overall, 118,394 patients underwent 1,511,740 treatments during the exposure period. Of 
these, 69,865 (59.0%) patients had UF rates <10 mL/h/kg, 26,794 (22.6%) had UF rates 10–
13 mL/h/kg, and 21,735 (18.4%) had UF rates >13 mL/h/kg. The median followup time was 
2.3 (interquartile range [IQR], 1.0–4.4) years, and there were 310,064 patient-years of total 
follow-up time. Mortality occurred at a rate of 15.3 deaths per 100 patient-years.
Primary Analyses
Unadjusted and adjusted associations between prescribed UF rate indexed to body weight 
and mortality are presented in Table 2. Prescribed UF rates >13 (versus ≤13) mL/h/kg were 
associated with greater mortality (adjusted HR, 1.31; 95% CI, 1.28–1.34). At a lower 
threshold, prescribed UF rates >10 (versus ≤10) mL/h/kg were also associated with greater 
mortality (adjusted HR, 1.22; 95% CI, 1.20–1.24). As we lacked data on residual urine 
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output, we performed analyses restricted to patients with dialysis vintages ≥4 years (n= 
40,706). Results were analogous to those of the full cohort (Table 2). We observed a dose-
response association between UF rate and mortality, with more frequent exposure to elevated 
UF rates associated with increased harm. Compared with <25% of treatments above the 
threshold, incrementally greater proportions of treatments with UF rates >13 mL/h/kg were 
associated with incrementally greater mortality (adjusted HRs of 1.26 [95% CI, 1.23–1.29] 
for 25%–49% of treatments and 1.40 [95% CI, 1.36–1.43] for ≥50% of treatments).
Sensitivity Analyses Related to Exposure Specification
In secondary analyses considering more finely categorized UF rates, mortality risk increased 
incrementally across successively greater UF rate categories (Table 3). When UF rate was 
considered continuously, mortality risk rose by 3% for every 1 mL/h/kg UF rate increase.
Delivered and prescribed UF rates were highly correlated (r=0.96; p<0.005). Results from 
analyses considering the delivered UF rate–mortality association were analogous to primary 
prescribed UF rate results (Table S3). To investigate the association of UF rates and 
mortality without influence from risk incurred during the long interdialytic interval, we 
performed analyses excluding HD treatments following the 72 hour interdialytic interval. 
Results were consistent with full cohort findings (Table S4). Results from models 
investigating time-updated prescribed UF rate and mortality were also analogous to primary 
findings (Item S1).
Subgroup Analyses
Table 4 displays results from subgroup analyses. Higher prescribed UF rate (across all 
specifications) was associated with significantly greater mortality in all subgroups studied. 
When UF rate was dichotomized at 13 mL/h/kg, this association was more pronounced in 
blacks versus non-blacks, non-Hispanics versus Hispanics, patients with dialysis vintage ≥4 
years versus <4 years, patients with session durations ≥ 4 hours versus <4 hours, and heavier 
versus lighter patients (p for interaction <0.05 for all, indicating that subgroup effect size 
differences were significant). Similarly, prescribed UF rate considered continuously (per 1 
mL/h/kg) was associated with greater mortality across all subgroups. Effect sizes were 
significantly greater among females versus males, non-Hispanics versus Hispanics, patients 
with dialysis vintage <4 years versus ≥4 years, and heavier versus lighter patients (p for 
interaction < 0.05 for all).
Body Size Influence
When prescribed UF rate was normalized to BMI, UF rates >37 (versus ≤37 [the 80th 
percentile]) mL/h/kg/m2 were associated with increased mortality (adjusted HR, 1.27; 95% 
CI, 1.24–1.30). When normalized to BSA, UF rates >500 (versus ≤500 [the 80th percentile]) 
mL/h/m2 were associated with increased mortality (adjusted HR, 1.23; 95% CI, 1.20–1.26). 
Using the Vuong test, modeling UF rate normalized to weight (compared to BMI and BSA, 
separately) was most predictive of mortality (p<0.001 for both).18
To further explore the UF rate–mortality association across body sizes, we categorized body 
size as <20th, 20th–80th, and >80th percentile of post-HD body weight, BMI and BSA 
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(separately). Again, UF rates >13 (versus ≤13) mL/h/kg were associated with greater death 
risk in each subgroup. The association was strongest among patients with higher versus 
lower body weight and at higher versus lower BMI. The magnitude of association was 
similar across BSA strata (Figure 3).
Ultrafiltration Rate Quality Measure Considerations
As the proposed CMS Quality Incentive Program (QIP) UF rate measure excludes patients 
with prescribed session durations ≥4 h from the metric numerator, we performed analyses 
restricted to patients with prescribed session durations ≥4h (n=39,890). Among patients with 
session durations ≥4h, prescribed UF rates >13 (versus ≤13) mL/h/kg and prescribed UF 
rates >10 (versus ≤10) mL/h/kg were associated with greater mortality, regardless of body 
size. These associations were more pronounced in heavier patients (>80th percentile of body 
weight) versus lighter patients (Table 5).
DISCUSSION
Prior studies have shown associations between rapid fluid removal and mortality among HD 
patients, but questions about study design and potential differences across subpopulations 
remain. In the largest to-date observational cohort, we demonstrated an association between 
greater UF rate and mortality, showing incrementally greater harm from UF rates starting at 
6 mL/h/kg. Our results suggest that notable UF-related harm begins before 10 mL/h/kg, 
substantially lower than the proposed quality measure threshold of 13 mL/h/kg. The UF 
rate–mortality association was significant across all body sizes, with larger patients having 
greater mortality risk from higher UF rates. Ultrafiltration rate normalized to body weight 
had a stronger association with mortality (versus normalization to BMI or BSA). Findings 
were robust across key sub-populations.
To date, three observational studies have examined the UF rate–mortality association. There 
have been no randomized-controlled trials. In a DOPPS (Dialysis Outcomes Practice 
Patterns Study) analysis, Saran et al. demonstrated a modest association between UF rates 
>10 mL/h/kg and all-cause mortality.2 In an Italian cohort, Movilli et al. identified a UF rate 
threshold of 12.2 mL/h/kg as the most predictive cut-point of mortality.3 In a post-hoc 
analysis of the Hemodialysis (HEMO) Study, Flythe et al. found that UF rates >13 mL/h/kg 
(versus <10 mL/h/kg) were associated with greater mortality.4 Effect modification on the 
basis of heart failure was observed, suggesting that risk may occur at rates of 10 mL/h/kg in 
some populations. In fact, spline analyses showed that the UF rate risk began to rise at 10 
mL/h/kg among all patients.4 Mechanistic studies evaluating intradialytic echocardiography, 
troponin and endotoxin have established hemodynamic-induced end-organ ischemia as a 
potential mediator of the UF rate–mortality association.5,6,8,21
Despite consistent findings across existing epidemiologic studies, the methodological 
shortcomings of these investigations have tempered enthusiasm for UF rate clinical 
guidelines.22–24 We sought to address these uncertainties. The IDWG (or UF volume), 
session duration, and post-HD weight all contribute to the UF rate calculation and were 
included in prior multivariable models, potentially introducing effect size inaccuracies. In 
our new analyses, we did not adjust for these factors as controlling for these variables 
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obscures interpretation of findings. Stated otherwise, accepting that high UF rate must result 
from high IDWG, low session duration, low body weight, or some combination thereof, we 
did not artificially constrain these factors analytically but accepted their inherent 
contributions to UF rate. Additionally, concern for confounding from residual kidney 
function has led to scrutiny of prior studies as urine output is a critical confounder.23 To 
address this, we performed analyses restricted to patients on dialysis for ≥4 years, a 
population with generally low urine output.
Our present analyses demonstrate that prescribed (and delivered) UF rates >10 mL/h/kg are 
associated with greater mortality. This finding is consistent with Saran et al. and the Flythe 
et al. spline analysis showing a steep rise in UF rate–related mortality risk at 10 mL/h/kg.2,4 
An UF rate threshold of 13 mL/h/kg, as instituted in the Core Survey and as proposed for the 
2019 CMS QIP, is likely conservative.9,10 Additionally, the National Quality Forum–
endorsed UF rate measure includes a session length restriction. The metric numerator 
includes only patients with UF rates ≥13 mL/h/kg and delivered session durations <4 hours. 
While this restriction may be in-line with patient preference data showing aversion to longer 
session lengths,25 our data demonstrate that patients with longer session durations incur 
greater mortality risk at higher UF rates. We also observed a dose-response association 
between UF rate and mortality: more frequent exposure to higher UF rates is associated with 
an incrementally higher death risk. Frequency-based definitions of UF rates may better 
capture risk than single treatment or mean-based UF rate definitions. Reassuringly, we 
observed the UF rate–mortality association to be robust across subgroups, rendering a single 
mean-based threshold approach reasonable. We also observed similar associations between 
prescribed and delivered UF rates and mortality, providing reassurance regarding the 
proposed quality measure’s capture of delivered UF rates. Together, these data provide 
strong observational evidence supporting an association between greater UF rates and 
mortality.
Fluid removal–related harm occurs when the UF rate exceeds the plasma refill rate and 
subclinical or clinical hemodynamic compromise occurs. Vascular refill is influenced by 
many factors including body size, sex, nutritional status, total body volume status and 
distribution, and blood flow distribution.26 It is plausible that the UF rate–outcome 
association varies across body types. Therefore, we considered fluid removal normalized to 
body weight, BMI and BSA. Ultrafiltration rate normalized to weight had the strongest 
association with mortality, but, when UF rate was modeled continuously, the effect size 
varied across sex and body size with females (versus males) and heavier (versus lighter) 
patients having greater mortality risk. Similar effect size differences were observed when UF 
rate was normalized to BMI. Normalizing UF rate to BSA produced more stable effect 
estimates across BSA strata. The ideal indexing method might yield similar strengths of 
association across body sizes as observed with BSA. However, the effect size differences 
across body sizes when UF rate was normalized to both weight and BMI were modest, and 
all three normalization methods revealed significantly greater mortality with higher UF rates 
across all body sizes. As body weight is readily available for UF rate calculation in the clinic 
and effect sizes only modestly different across body size strata, UF rate normalization to 
body weight is reasonable.
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Several limitations of our study should be acknowledged. This is an observational analysis 
and may contain uncontrolled confounding. To minimize confounding from difficult-to-
measure factors such as health status, we controlled for variables including albumin, 
phosphate, creatinine, albumin, and weight. Related, we performed analyses restricted to 
patients of advanced dialysis vintage to minimize confounding from residual urine output. 
Nevertheless, we cannot rule out the possibility of confounding from these factors or other 
unconsidered factors. For example, body size, clearance, and session duration are closely 
related. Despite including URR and body size (via UF rate) in our models, we cannot rule-
out residual confounding from clearance and body size-related factors. We also lacked data 
on dialysate and dietary sodium, potential confounders of the UF rate–mortality association. 
Reassuringly, the addition of serum sodium to multivariable models did not substantially 
alter UF rate–mortality effect estimates (Table S5), but residual confounding from these and 
other factors cannot be excluded. Prospective study of UF rate and outcomes is warranted. 
Second, we were unable to investigate cause-specific mortality due to lack of adjudicated 
death causes in our database. Third, we were unable to consider intradialytic symptoms due 
to lack of symptom data. Fourth, our data were derived from a single LDO and may not be 
representative of other dialysis providers. Finally, our study included adult, in-center 
maintenance HD patients with dialytic vintage ≥90 days. Results should not be extrapolated 
to excluded populations such as incident HD patients.
In conclusion, we demonstrated an association between UF rates >10 mL/h/kg (versus ≤10) 
and all-cause mortality and showed an incremental rise in UF-related risk beginning at a UF 
rate of 6 mL/h/kg. Additionally, we found the UF rate–outcome association to be robust 
across body size, sex, and racial subgroups and provided evidence supporting normalization 
of UF rate to weight versus other anthropometric metrics. The richness of the UF rate–
outcome observational evidence base and the regulatory interest in adoption of an UF rate 
quality measure calls for a randomized controlled trial investigation of UF rates and 
outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank DaVita Clinical Research for providing data for this study. DaVita Clinical Research had no role 
in the design or implementation of this study or the decision to publish. The authors thank Alan Brookhart for data 
access and his insightful comments on analyses and Diane Reams for her data and contract management assistance.
Support: Dr Assimon is supported by National Institute of Diabetes and Digestive and Kidney Diseases training 
grant T32 DK007750.
References
1. Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 annual data report. Am J 
Kidney Dis. 2014; 63(1 (suppl 1)):e1–e420.
2. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in 
hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006; 69(7):1222–
1228. [PubMed: 16609686] 
Assimon et al. Page 9
Am J Kidney Dis. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3. Movilli E, Gaggia P, Zubani R, et al. Association between high ultrafiltration rates and mortality in 
uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. 
Nephrol Dial Transplant. 2007; 22(12):3547–3552. [PubMed: 17890254] 
4. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with 
cardiovascular morbidity and mortality. Kidney Int. 2011; 79(2):250–257. [PubMed: 20927040] 
5. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: 
determinants and associated outcomes. Clin J Am Soc Nephrol. 2009; 4(5):914–920. [PubMed: 
19357245] 
6. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial 
injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc 
Nephrol. 2009; 4(12):1925–1931. [PubMed: 19808220] 
7. Eldehni MT, Odudu A, McIntyre CW. Randomized Clinical Trial of Dialysate Cooling and Effects 
on Brain White Matter. J Am Soc Nephrol. 2014; 24(4):957–965.
8. McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia: a novel factor in systemic 
inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol. 2011; 
6(1):133–141. [PubMed: 20876680] 
9. Centers for Medicare and Medicaid Services. Proposed Measure Specifications for the PY 2019 
ESRD QIP. Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
Instruments/ESRDQIP/Downloads/ESRDQIPSummaryPaymentYears2014-2018.pdf. Accessed 
February 4, 2016
10. Centers for Medicare and Medicaid Services. Release of Fiscal Year 2016 End Stage Renal Disease 
Core Survey Data Worksheet. 2015. Available at https://www.cms.gov/Medicare/Provider-
Enrollment-and-Certification/GuidanceforLawsAndRegulations/Downloads/ESRD-Core-Survey-
Data-Worksheet.pdf. Accessed February 4, 2016
11. Farrar D, Glauber R. Multicollinearity in regression analysis: the problem revisited. The Review of 
Economics and Statistics. 1967; 1:92–107.
12. National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 
2015 Update. Am J Kidney Dis. 2015; 66(5):884–930. [PubMed: 26498416] 
13. Agar JW. Personal viewpoint: Limiting maximum ultrafiltration rate as a potential new measure of 
dialysis adequacy. Hemodial Int. 2016; 20(1):15–21. [PubMed: 25779217] 
14. National Quality Forum. Renal Draft Report. Available at https://www.google.com/url?
sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwja5cqlzr7JAhXDP
iYKHTQUCHUQFggcMAA&url=http%3A%2F%2Fwww.qualityforum.org%2FProjects%2Fn-r
%2FRenal_Measures
%2FDraft_Report_for_Comment.aspx&usg=AFQjCNFGMoefydMrs7WvIqT7_l1_3wncjw&sig2
=f0jP__24ngTVnc9pohVNBA. Accessed February 4, 2016
15. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight 
be known. 1916. Nutrition. 1989; 5(5):303–311. discussion 312–303. [PubMed: 2520314] 
16. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need 
competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013; 
28(11):2670–2677. [PubMed: 23975843] 
17. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999; 8(1):3–15. [PubMed: 
10347857] 
18. Vuong Q. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica. 
1989; 57(2):307–334.
19. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in 
epidemiology. Epidemiology. 2000; 11(5):550–560. [PubMed: 10955408] 
20. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of 
zidovudine on the survival of HIV-positive men. Epidemiology. 2000; 11(5):561–570. [PubMed: 
10955409] 
21. Eldehni MT, McIntyre CW. Are there neurological consequences of recurrent intradialytic 
hypotension? Semin Dial. 2012; 25(3):253–256. [PubMed: 22353138] 
22. End Stage Renal Disease (ESRD) Quality Measure Development and Maintenance Hemodialysis 
Adequacy Clinical Technical Expert Panel Summary Report. Arbor Research Collaborative for 
Assimon et al. Page 10
Am J Kidney Dis. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Health and the University of Michigan Kidney Epidemiology and Cost Center. 2013. Available at 
http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/
Downloads/Hemodialysis-Adequacy-TEP-Summary-Report-and-Addendum.pdf. Accessed 
February 4, 2016
23. Arora N, Chertow GM. Oh! What a tangled web we weave. Clin J Am Soc Nephrol. 2013; 8(7):
1066–1067. [PubMed: 23766364] 
24. Assimon MM, Flythe JE. Intradialytic Blood Pressure Abnormalities: The Highs, The Lows and 
All That Lies Between. Am J Nephrol. 2015; 42(5):337–350. [PubMed: 26584275] 
25. Flythe JE, Mangione TW, Brunelli SM, Curhan GC. Patient-Stated Preferences Regarding Volume-
Related Risk Mitigation Strategies for Hemodialysis. Clin J Am Soc Nephrol. 2014; 9(8):1418–
1425. [PubMed: 24903386] 
26. Schneditz D, Roob J, Oswald M, et al. Nature and rate of vascular refilling during hemodialysis 
and ultrafiltration. Kidney Int. 1992; 42(6):1425–1433. [PubMed: 1474776] 
Assimon et al. Page 11
Am J Kidney Dis. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Study design schematic
a
 Source cohort consisted of 337,863 in-center hemodialysis patients with complete age, sex, 
race and ethnicity data.
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Figure 2. 
Flow-chart of cohort selection.
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Figure 3. Associations between prescribed ultrafiltration rate and mortality by percentile of post-
dialysis weight, body mass index and body surface area
Fine and Gray proportional subdistribution hazards regression models with kidney 
transplantation and dialysis modality change treated as competing risks were used to 
estimate the ultrafiltration rate and all-cause mortality association comparing mean UF rates 
>13 mL/h/kg to those ≤13 mL/h/kg within strata of body weight, BMI and BSA (separately). 
Models were adjusted for age (continuous), sex (female vs. male), race (black vs. non-
black), ethnicity (Hispanic vs. non-Hispanic), dialysis vintage (1–2, 3–4, ≥5 vs. <1 year), 
vascular access (graft, fistula vs. catheter), history of heart failure (yes vs. no), history of 
cardiovascular disease (yes vs. no), history of diabetes (yes vs. no), albumin (3.1–3.5, 3.6–
4.0, >4.0 vs. ≤3.0 g/dL), creatinine (continuous), phosphorous (4.1–5.0, 5.1–6.0, >6.0 vs. 
≤4.0 mg/dL), hemoglobin (10.0–11.9, ≥12.0 vs. <10.0 g/dL), urea reduction ratio 
(continuous), pre-HD systolic blood pressure (131–150, 151–170, >170 vs. ≤130 mmHg), 
and missed sessions (≥3 vs. <3).
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Post-dialysis weight was used to calculate normalized UF rates for weight, BMI and BSA. 
20th/80th percentile for post-weight = 60.9/95.3 kg; 21.8/32.8 kg/m2 for BMI; 1.66/2.10 m2 
for BSA. 80th percentile for UF rate normalized to BMI = 37 mL/h/(kg/m2); UF rate 
normalized to BSA = 500 mL/h/m2. 80th percentile selected for BMI and BSA based on 13 
mL/h/kg being the 80th percentile of UF rate when normalized to post-HD weight.
Abbreviations: HR=hazard ratio, CI=confidence interval, HD=hemodialysis
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Table 1
Baseline characteristics across prescribed ultrafiltration rate groups.
Total (N=118,394)b
30-d mean prescribed UF rate
<10 mL/h/kg 
(n=69,865 [59.0%]b
10–13 mL/h/kg 
(n=26,794 [22.6%])b
>13 mL/h/kg 
(n=21,735 [18.4%])b
UF rate
 pmL/h/kg 9.4 ± 4.3 6.6 ± 2.5 11.4 ± 0.9 16.0 ± 2.9
 mL/h/kg/m2 27.2 ± 13.2 (n=118,215) 19.5 ± 8.5 (n=69,743) 32.8 ± 6.4 (n=26,765) 45.0 ± 10.8 (n=21,707)
 mL/h/m2 377.2 ± 154.2 (n=118,215) 286.3 ± 107.7 
(n=69,768)
451.1 ± 70.0 
(n=26,765)
578.3 ± 111.8 
(n=21,707)
Age (y) 61 ± 15 62 ± 15 61 ± 15 58 ± 16
Female sex 53,307 (45.0) 30,964 (44.3) 11,554 (43.1) 10,789 (49.6)
Black race 45,289 (38.3) 28,584 (40.9) 9,713 (36.3) 6,992 (32.2)
Hispanic ethnicity 19,520 (16.5) 9,823 (14.1) 5,108 (19.1) 4,589 (21.1)
History of heart failure 31,534 (26.6) 16,775 (24.0) 7,911 (29.5) 6,848 (31.5)
History of CVD 66,988 (56.6) 37,999 (54.4) 15,864 (59.2) 13,125 (60.4)
History of diabetes 61,721 (52.1) 36,085 (51.6) 14,467 (54.0) 11,169 (51.4)
Dialysis vintage
 <1 y 25,283 (21.4) 16,874 (24.2) 4,963 (18.5) 3,446 (15.9)
 1–2 y 39,411 (33.3) 23,995 (34.3) 8,788 (32.8) 6,628 (30.5)
 3–4 y 22,718 (19.2) 12,842 (18.4) 5,404 (20.2) 4,472 (20.6)
 ≥5 y 30,982 (26.2) 16,154 (23.1) 7,639 (28.5) 7,189 (33.1)
Vascular access
 Graft 25,743 (21.7) 14,323 (20.5) 6,184 (23.1) 5,236 (24.1)
 Fistula 61,991 (52.4) 35,226 (50.4) 14,784 (55.2) 11,981 (55.1)
 Catheter 30,660 (25.9) 20,316 (29.1) 5,826 (21.7) 4,518 (20.8)
Post-HD weight (kg) 79.2 ± 22.4 84.6 ± 23.7 75.6 ± 18.3 73.5 ± 6.5
IDWG (kg) 2.9 ± 2.2 2.5 ± 2.1 3.3 ± 2.0 3.6 ± 2.2
BMI (kg/m2) 27.7 ± 7.3 (n=118,215) 29.3 ± 7.8 (n=69,743) 26.6 ± 6.1 (n=26,765) 23.9 ± 5.1 (n=21,707)
BSA (m2) 1.9 ± 0.3 (n=118,215) 2.0 ± 0.3 (n=69,768) 1.9 ± 0.2 (n=26,765) 1.7 ± 0.2 (n=21,707)
Prescribed session duration (min) 218 ± 36 223 ± 39 214 ± 28 205 ± 28
Pre-HD SBP
 ≤130 m Hg 28,766 (24.3) 17,419 (24.9) 6,403 (23.9) 4,944 (22.7)
 131–150 mm Hg 34,102 (28.8) 20,217 (28.9) 7,783 (29.0) 6,102 (28.1)
 151–170 mm Hg 30,279 (25.6) 17,640 (25.2) 6,934 (25.9) 5,705 (26.2)
 ≥171 mm Hg 25,247 (21.3) 14,589 (20.9) 5,674 (21.2) 4,984 (22.9)
Missed sessions ≥3 23,590 (19.9) 13,590 (19.5) 5,183 (19.3) 4,817 (22.2)
Albuminc
 ≤3.0 g/dL 6,390 (5.4) 3,932 (5.6) 1,216 (4.5) 1,242 (5.7)
 3.1–3.5 g/dL 19,852 (16.8) 11,829 (16.9) 4,255 (15.9) 3,768 (17.3)
 3.6–4.0 g/dL 56,005 (47.3) 33,335 (47.7) 12,785 (47.7) 9,885 (45.5)
 >4.0 g/dL 36,147 (30.5) 20,769 (29.7) 8,538 (31.9) 6,840 (31.5)
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Total (N=118,394)b
30-d mean prescribed UF rate
<10 mL/h/kg 
(n=69,865 [59.0%]b
10–13 mL/h/kg 
(n=26,794 [22.6%])b
>13 mL/h/kg 
(n=21,735 [18.4%])b
Serum sodium (mEq/L)c 138.2 ± 2.1 138.4 ± 2.0 138.2 ± 2.1 137.8 ± 2.3
Creatinine (mg/dL)c 8.3 ± 3.1 8.1 ± 3.1 8.6 ± 3.1 8.6 ± 3.1
Phosphorousc
 ≤4.0 mg/dL 23,431 (19.8) 14,849 (21.3) 4,815 (18.0) 3,767 (17.3)
 4.1–5.0 mg/dL 33,958 (28.7) 20,981 (30.0) 7,553 (28.2) 5,424 (25.0)
 5.1–6.0 mg/dL 29,464 (24.9) 17,376 (24.9) 6,754 (25.2) 5,334 (24.5)
 >6.0 mg/dL 31,541 (26.6) 16,659 (23.8) 7,672 (28.6) 7,210 (33.2)
Hemoglobinc
 <10.0 g/dL 12,805 (10.8) 7,373 (10.6) 2,713 (10.1) 2,719 (12.5)
 10.0–11.9 g/dL 56,405 (47.6) 33,526 (48.0) 12,680 (47.3) 10,199 (46.9)
 ≥12.0 g/dL 49,184 (41.5) 28,966 (41.5) 11,401 (42.6) 8,817 (40.6)
Urea reduction ratio (%)c 73.0 ± 6.8 72.8 ± 7.0 73.2 ± 6.5 73.5 ± 6.5
Note: Values for categorical variables are given as number (percentage); for continuous variables, as mean ± standard deviation.
b
Total n except where noted.
c
Imputed using Markov chain Monte Carlo method using 10 imputations when missing (n=2,184 for albumin, n=88,218 for serum sodium, 
n=7,473 for creatinine, n=1,430 for phosphorus, n=627 for hemoglobin, and n=1,642 for urea reduction ratio).
Abbreviations: BMI, body mass index; BSA, body surface area; CVD=cardiovascular disease, HD=hemodialysis, IDWG=interdialytic weight gain, 
SBP=systolic blood pressure, UF=ultrafiltration.
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Table 2
Associations between prescribed ultrafiltration rate and all-cause mortality among all patients and patients 
with longer dialysis vintage.
n (%) Unadjusted HR (95%CI) Adjustedb HR (95% CI)
Full Cohort (N=118,394)
Mean UF rate dichotomized at 10 mL/h/kg
 ≤10 mL/h/kg 69,865 (59.0) 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 48,529 (41.0) 1.10 (1.08–1.12) 1.22 (1.20–1.24)
Mean UF rate dichotomized at 13 mL/h/kg
 ≤13 mL/h/kg 96,659 (81.6) 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 21,735 (18.4) 1.15 (1.12–1.17) 1.31 (1.28–1.34)
Mean UF rate categorized
 <10 mL/h/kg 69,865 (59.0) 1.00 (reference) 1.00 (reference)
 10–13 mL/h/kg 26,794 (22.6) 1.05 (1.03–1.07) 1.12 (1.10–1.15)
 >13 mL/h/kg 21,735 (18.4) 1.16 (1.14–1.19) 1.35 (1.32–1.39)
Restricted Cohort: Dialysis Vintage ≥4 Y (n=40,706)
Mean UF rate dichotomized at 10 mL/h/kg
 ≤10 mL/h/kg 21,470 (52.7) 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 19,236 (47.3) 1.03 (1.00–1.06) 1.19 (1.15–1.23)
Mean UF rate dichotomized at 13 mL/h/kg
 ≤13 mL/h/kg 31,488 (77.4) 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 9,218 (22.6) 1.05 (1.02–1.09) 1.26 (1.21–1.30)
Mean UF rate categorized
 <10 mL/h/kg 21,470 (52.7) 1.00 (reference) 1.00 (reference)
 10–13 mL/h/kg 10,018 (24.6) 1.00 (0.97–1.04) 1.10 (1.06–1.15)
 >13 mL/h/kg 9,218 (22.6) 1.05 (1.02–1.10) 1.30 (1.25–1.35)
Note:
 Fine and Gray proportional subdistribution hazards regression models with kidney transplantation and dialysis modality change treated as 
competing risks were used to estimate the ultrafiltration rate and all-cause mortality association.
bAdjusted for baseline age (continuous), sex (female vs. male), race (black vs. non-black), ethnicity (Hispanic vs. non-Hispanic), dialysis vintage 
(1–2, 3–4, ≥5 vs. <1 year), vascular access (graft, fistula vs. catheter), history of heart failure (yes vs. no), history of cardiovascular disease (yes vs. 
no), history of diabetes (yes vs. no), albumin (3.1–3.5, 3.6–4.0, >4.0 vs. ≤3.0 g/dL), creatinine (continuous), phosphorous (4.1–5.0, 5.1–6.0, >6.0 
vs. ≤ 4.0 mg/dL), hemoglobin (10.0–11.9, ≥12.0 vs. <10.0 g/dL), urea reduction ratio (continuous), pre-hemodialysis systolic blood pressure (131–
150, 151–170, >170 vs. ≤130 mmHg), missed sessions (≥3 vs. <3). Subgroups of interest were excluded from the adjustments listed previously 
where applicable.
Abbreviations: HR=hazard ratio, CI=confidence interval, UF=ultrafiltration.
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Table 3
Associations between continuous and finely categorized prescribed ultrafiltration rate and all-cause mortality.
n (%)
HR (95% CI)
Unadjusted Adjustedb
Mean UF rate, mL/h/kg 118,394 (100.0%) 1.01 (1.01–1.02) 1.03 (1.02–1.03)
Mean UF rate
 <6 mL/h/kg 23,813 (20.1%) 1.00 (reference) 1.00 (reference)
 6–<8 mL/h/kg 21,729 (18.4%) 0.99 (0.96–1.02) 1.03 (1.00–1.07)
 8–<10 mL/h/kg 24,323 (20.5%) 1.01 (0.98–1.04) 1.09 (1.06–1.12)
 10–<12 mL/h/kg 19,457 (16.4%) 1.04 (1.01–1.07) 1.15 (1.12–1.19)
 12–<14 mL/h/kg 13,086 (11.1%) 1.08 (1.05–1.12) 1.23 (1.18–1.27)
 ≥14 mL/h/kg 15,986 (13.5%) 1.19 (1.15–1.23) 1.43 (1.39–1.48)
Note: Fine and Gray proportional subdistribution hazards regression models with kidney transplantation and dialysis modality change treated as 
competing risks were used to estimate the ultrafiltration rate and all-cause mortality association.
bAdjusted for baseline age (continuous), sex (female vs. male), race (black vs. non-black), ethnicity (Hispanic vs. non-Hispanic), dialysis vintage 
(1–2, 3–4, ≥5 vs. <1 year), vascular access (graft, fistula vs. catheter), history of heart failure (yes vs. no), history of cardiovascular disease (yes vs. 
no), history of diabetes (yes vs. no), albumin (3.1–3.5, 3.6–4.0, >4.0 vs. ≤3.0 g/dL), creatinine (continuous), phosphorous (4.1–5.0, 5.1–6.0, >6.0 
vs. ≤ 4.0 mg/dL), hemoglobin (10.0–11.9, ≥12.0 vs. <10.0 g/dL), urea reduction ratio (continuous), pre-hemodialysis systolic blood pressure (131–
150, 151–170, >170 vs. ≤130 mmHg), missed sessions (≥3 vs. <3).
Abbreviations: HR=hazard ratio, CI=confidence interval, UF=ultrafiltration.
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Table 4
Associations between prescribed ultrafiltration rate and mortality within subgroups of interest.
Sex Female (n=53,307) Male (n=65,087) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg <0.001
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.26 (1.23–1.30) 1.18 (1.15–1.21)
Mean UF rate dichotomized at 13 mL/h/kg 0.2
 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.33 (1.29–1.37) 1.29 (1.25–1.33)
Mean UF rate continuous (mL/h/kg) 1.03 (1.03–1.03) 1.02 (1.02–1.03) 0.004
Race Non-Black (n=73,105) Black (n=45,289) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg 0.6
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.21 (1.19–1.24) 1.23 (1.19–1.27)
Mean UF rate dichotomized at 13 mL/h/kg 0.004
 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.28 (1.24–1.31) 1.38 (1.32–1.43)
Mean UF rate continuous (mL/h/kg) 1.03 (1.02–1.03) 1.03 (1.03–1.03) 0.2
Ethnicity Non-Hispanic (n=98,874) Hispanic (n=19,520) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg 0.1
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.23 (1.20–1.25) 1.17 (1.12–1.23)
Mean UF rate dichotomized at 13 mL/h/kg 0.002
 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.33 (1.29–1.36) 1.20 (1.14–1.27)
Mean UF rate continuous (mL/h/kg) 1.03 (1.02–1.03) 1.02 (1.01–1.03) 0.03
Dialysis Vintage <4 y (n=77,688) ≥4 y (n=40,706) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg <0.001
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.17 (1.13–1.21) 1.25 (1.22–1.28)
Mean UF rate dichotomized at 13 mL/h/kg <0.001
 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.23 (1.19–1.28) 1.37 (1.33–1.41)
Mean UF rate continuous (mL/h/kg) 1.03 (1.02–1.03) 1.02 (1.02–1.03) 0.007
Session Duration <4 h (n=78,504) ≥4 h (n=39,890) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg 0.9
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.22 (1.20–1.25) 1.23 (1.19–1.27)
Mean UF rate dichotomized at 13 mL/h/kg 0.02
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 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.30 (1.26–1.33) 1.39 (1.32–1.46)
Mean UF rate continuous (mL/h/kg) 1.03 (1.02–1.03) 1.03 (1.02–1.03) 0.09
Post-HD Weight <20th percentilec (n=23,524) >80th percentilec (n=23,646) P for interactionb
Mean UF rate dichotomized at 10 mL/h/kg 0.2
 ≤10 mL/h/kg 1.00 (reference) 1.00 (reference)
 >10 mL/h/kg 1.14 (1.10–1.19) 1.22 (1.16–1.29)
Mean UF rate dichotomized at 13 mL/h/kg <0.001
 ≤13 mL/h/kg 1.00 (reference) 1.00 (reference)
 >13 mL/h/kg 1.15 (1.11–1.20) 1.36 (1.22–1.51)
Mean UF rate continuous (mL/h/kg) 1.01 (1.01–1.02) 1.02 (1.02–1.03) <0.001
Except where indicated, values shown are Adjusteda HR (95% confidence interval).
a
Fine and Gray proportional subdistribution hazards regression models with kidney transplantation and dialysis modality change treated as 
competing risks were used to estimate the ultrafiltration rate and all-cause mortality association. Adjusted for age (continuous), sex (female vs. 
male), race (black vs. non-black), ethnicity (Hispanic vs. non-Hispanic), dialysis vintage (1–2, 3–4, ≥5 vs. <1 year), vascular access (graft, fistula 
vs. catheter), history of heart failure (yes vs. no), history of cardiovascular disease (yes vs. no), history of diabetes (yes vs. no), albumin (3.1–3.5, 
3.6–4.0, >4.0 vs. ≤3.0 g/dL), creatinine (continuous), phosphorous (4.1–5.0, 5.1–6.0, >6.0 vs. ≤ 4.0 mg/dL), hemoglobin (10.0–11.9, ≥12.0 vs. 
<10.0 g/dL), urea reduction ratio (continuous), pre-HD systolic blood pressure (131–150, 151–170, >170 vs. ≤130 mmHg), missed sessions (≥3 vs. 
<3). Effect modifiers of interest were excluded from the adjustments listed above.
bSignificance of interaction terms was determined using the Wald test.
c
Post-HD weight 20th percentile = 60.9 kg and 80th percentile = 95.3 kg. The 20th–80th percentile was included in the model but is not shown.
Abbreviations: Abbreviations: HR=hazard ratio, CI=confidence interval, UF=ultrafiltration, HD= hemodialysis, pct=percentile.
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Table 5
Associations between prescribed ultrafiltration rate and mortality overall and by percentile of post-HD weight 
in patients with prescribed session durations ≥4 hours.
All
Post-HD weight
<20th percentile: <70.9 
kg
20th–80th percentile: 
70.9–110.2 kg >80th percentile:>110.2 kg
No. of patients 39,890 7,925 24,009 7,956
IDWG (kg) 3.5 ± 2.3 2.8 ± 2.2 3.4 ± 2.2 4.3 ± 2.4
Prescribed session duration (min) 253 ± 34 247 ± 31 250 ± 31 265 ± 42
Associations**
 Mean UF rate dichotomized at 10 
mL/h/kg
  ≤10 mL/h/kg 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
  >10 mL/h/kg 1.23 (1.18–1.27) 1.08 (1.01–1.16)* 1.18 (1.13–1.24)* 1.39 (1.24–1.55)*
 Mean UF rate dichotomized at 13 
mL/h/kg
  ≤13 mL/h/kg 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
  >13 mL/h/kg 1.38 (1.31–1.45) 1.21 (1.12–1.31)* 1.32 (1.23–1.43)* 1.76 (1.41–2.18)*
 Mean UF rate categorized
  <10 mL/h/kg 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
  10–13 mL/h/kg 1.14 (1.09–1.18) 0.98 (0.90–1.06)* 1.12 (1.06–1.18)* 1.31 (1.16–1.48)*
  >13 mL/h/kg 1.42 (1.35–1.50) 1.20 (1.11–1.31)* 1.36 (1.26–1.48)* 1.81 (1.45–2.25)*
Note: Unless otherwise indicated, values are given as mean ± standard deviation.
*
Interaction term significant at p<0.01.
**Values given as adjusteda HR (95% CI)
a
Fine and Gray proportional subdistribution hazards regression models with kidney transplantation and dialysis modality change treated as a 
competing risks were used to estimate the ultrafiltration rate and all-cause mortality association. Models are adjusted for age (continuous), sex 
(female vs. male), race (black vs. non-black), ethnicity (Hispanic vs. non-Hispanic), dialysis vintage (1–2, 3–4, ≥5 vs. <1 year), vascular access 
(graft, fistula vs. catheter), history of heart failure (yes vs. no), history of cardiovascular disease (yes vs. no), history of diabetes (yes vs. no), 
albumin (3.1–3.5, 3.6–4.0, >4.0 vs. ≤3.0 g/dL), creatinine (continuous), phosphorous (4.1–5.0, 5.1–6.0, >6.0 vs. ≤ 4.0 mg/dL), hemoglobin (10.0–
11.9, ≥12.0 vs. <10.0 g/dL), urea reduction ratio (continuous), pre-HD systolic blood pressure (131–150, 151–170, >170 vs. ≤130 mmHg), missed 
sessions (≥3 vs. <3). Subgroups of interest were excluded from the adjustments listed above. Significance of interaction terms was determined 
using Wald chi-square (type 3) tests.
Abbreviations: CI, confidence interval; UF=ultrafiltration, HD=hemodialysis, HR, hazard ratio; IDWG=interdialytic weight gain,
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